Evidence map›Paper›PMID 41843026›Full record

ReviewDiscover nano2026

Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.

Sandip M Sonwane, Rahul G Ingle

Abstract readReview
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sandip M SonwaneDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, (DU), Sawangi, Wardha, Maharashtra, 442001, India.
Rahul G IngleDatta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, (DU), Sawangi, Wardha, Maharashtra, 442001, India. rahul.pharmacy@dmiher.edu.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copper-based metal organic frameworks (Cu-MOFs) represent a highly versatile family of porous crystalline materials valued for their tunable structures, redox-active Cu centers, and inherent biodegradability, which collectively increase their therapeutic and technological potential. This review provides an integrated overview of recent progress in synthetic approaches ranging from solvothermal and mechanochemical techniques to more sustainable, scalable green processes and emphasizes how precise control over coordination chemistry, defect formation, and surface engineering governs their physicochemical performance. Major biomedical advancements are highlighted, particularly their role as both drug delivery platforms and active therapeutic agents capable of generating reactive oxygen species for chemodynamic therapy, supporting synergistic phototherapies, and exerting antimicrobial effects, with innovations in stimuli-responsive designs and biomimetic modifications improving stability and targeting under physiological conditions. Additionally, the increasing importance of Cu-MOFs in catalysis, energy storage, and environmental remediation underscores their wide-ranging industrial significance. Nonetheless, challenges such as ensuring long-term biosafety, maintaining stability in biological environments, and achieving reproducible large-scale production continue to limit clinical translation. Future progress will rely on predictive design tools, deeper structure-function understanding, and standardized biological assessments. Overall, Cu-MOFs stand at the interface of materials science and biomedicine, with ongoing innovations poised to drive their evolution from promising laboratory systems into impactful real-world applications.

Indexed as

Biomedical applicationCu-MOFsSynthesis

Identifiers

PMID41843026
PMCPMC12996560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.